This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Deutsche Bank Remains a Hold on Novo Nordisk (0QIU)
In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Hold rating on Novo Nordisk, with a price target of DKK290.00.
Introducing TipRanks MCP for Agents
- Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools.
- Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.
Papadakis covers the Healthcare sector, focusing on stocks such as AstraZeneca, GlaxoSmithKline, and Sanofi. According to TipRanks, Papadakis has an average return of 3.4% and a 51.42% success rate on recommended stocks.
The word on The Street in general, suggests a Hold analyst consensus rating for Novo Nordisk with a DKK277.67 average price target.
0QIU market cap is currently DKK1208.8B and has a P/E ratio of 9.91.
Read More on GB:0QIU:
Disclaimer & DisclosureReport an Issue
- Novo Nordisk announces Reimagine 1-3 trials each met primary endpoint
- Novo Nordisk announces new evidence in adults with T2D treated with semaglutide
- Novo Nordisk to present new data on Wegovy across cardiometabolic conditions
- Veru pact with Novo ‘significant event,’ says Canaccord
- Veru announces clinical supply agreement with Novo Nordisk
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
